Migraine Medication: A Complete Guide to Acute and Preventive Treatments

Understanding Migraine Medication Categories

Treating migraine effectively requires understanding the two fundamental categories of medication. Acute (abortive) treatments are taken during an attack to relieve symptoms. Preventive (prophylactic) treatments are taken regularly, whether or not you have a headache, to reduce how often attacks occur and how severe they are [1]. Many patients with moderate to severe migraine benefit from both approaches working together.

The American Headache Society recommends considering preventive therapy when a patient experiences four or more migraine days per month, when attacks are significantly disabling, or when acute medications are not providing adequate relief [2].

Acute Migraine Medications

Triptans

Triptans have been the backbone of acute migraine treatment since sumatriptan was introduced in the early 1990s. They work by activating serotonin 5-HT1B and 5-HT1D receptors, which constricts dilated blood vessels and inhibits the release of inflammatory neuropeptides, including CGRP [3].

Seven triptans are currently available: sumatriptan, rizatriptan, eletriptan, zolmitriptan, naratriptan, almotriptan, and frovatriptan. They differ in how quickly they start working, how long they last, and how they are delivered [3]:

• Fastest onset: Sumatriptan injection (10 to 15 minutes), sumatriptan nasal spray (15 to 20 minutes), rizatriptan orally disintegrating tablet (30 minutes)
• Longest duration: Frovatriptan (half-life of 26 hours, making it useful for menstrual migraine prevention) and naratriptan (half-life of 6 hours)
• Best tolerated: Naratriptan and almotriptan tend to cause fewer side effects, though they may be slightly less potent

Common side effects include chest tightness, tingling, fatigue, and dizziness. Because triptans cause vasoconstriction, they are contraindicated in patients with coronary artery disease, uncontrolled hypertension, or a history of stroke [3].

Gepants (Small-Molecule CGRP Receptor Antagonists)

Gepants are a newer class of acute migraine treatment that block the CGRP receptor without causing vasoconstriction. This makes them a valuable option for patients who cannot take triptans due to cardiovascular risk [4]. Three gepants are currently approved for acute treatment:

• Ubrogepant (Ubrelvy): Oral tablet taken at onset of migraine, with an optional second dose after 2 hours
• Rimegepant (Nurtec ODT): Orally disintegrating tablet with a unique dual indication for both acute treatment and prevention
• Zavegepant (Zavzpret): Nasal spray offering faster onset than oral gepants

Clinical trials show gepants provide pain freedom at 2 hours in approximately 19 to 21 percent of patients compared to 11 to 14 percent with placebo [4]. While these numbers are modest compared to triptans, gepants carry no cardiovascular warnings and do not appear to cause medication overuse headache.

NSAIDs and Analgesics

Nonsteroidal anti-inflammatory drugs remain a first-line option for mild to moderate migraine attacks. Ibuprofen (400 to 800 mg), naproxen sodium (500 to 825 mg), and aspirin (900 to 1000 mg) all have evidence supporting their effectiveness [5]. Diclofenac potassium, available as a powder for oral solution, offers faster absorption than standard tablets.

For stronger acute relief, some physicians prescribe combination analgesics. The combination of acetaminophen, aspirin, and caffeine (sold as Excedrin Migraine in the US) is an FDA-approved over-the-counter option with good evidence behind it [5]. Caffeine enhances analgesic absorption and has mild vasoconstrictive effects that may help on their own.

Ditans (5-HT1F Receptor Agonists)

Lasmiditan (Reyvow) represents another option for patients who cannot take triptans. Unlike triptans, lasmiditan selectively activates the 5-HT1F receptor and does not cause vasoconstriction [6]. It is effective for acute migraine but causes significant dizziness and sedation in many patients. Driving and operating machinery should be avoided for at least 8 hours after a dose, and it is classified as a Schedule V controlled substance due to its CNS effects.

Antiemetics

Nausea and vomiting accompany migraine in many patients, making antiemetics an important part of acute treatment. Metoclopramide and prochlorperazine not only relieve nausea but also have independent antimigraine activity through dopamine receptor blockade [7]. In emergency department settings, IV prochlorperazine or metoclopramide is often more effective than opioids for acute migraine relief [7].

Preventive Migraine Medications

CGRP Monoclonal Antibodies

These biologic medications target either the CGRP molecule itself or its receptor and represent the first drug class developed specifically for migraine prevention. Four CGRP monoclonal antibodies are available [8]:

• Erenumab (Aimovig): Monthly self-injection targeting the CGRP receptor (70 mg or 140 mg)
• Fremanezumab (Ajovy): Monthly or quarterly self-injection targeting the CGRP ligand
• Galcanezumab (Emgality): Monthly self-injection targeting the CGRP ligand
• Eptinezumab (Vyepti): Quarterly IV infusion targeting the CGRP ligand, with the fastest onset of preventive benefit

Clinical trials consistently show that CGRP monoclonal antibodies reduce monthly migraine days by 3 to 5 days compared to 1 to 3 days with placebo [8]. Their side effect profile is remarkably clean: injection site reactions and constipation (particularly with erenumab) are the most common complaints. Unlike older preventive medications, they do not cause weight gain, cognitive dulling, or sedation.

The main barriers are cost and access. Without insurance coverage, these medications can exceed $600 per month, though manufacturer assistance programs and biosimilar competition are beginning to improve affordability [8].

Beta-Blockers

Propranolol and metoprolol have the strongest evidence among beta-blockers for migraine prevention [9]. They are thought to work through modulation of central catecholamine activity and regulation of vascular tone. Propranolol at doses of 80 to 240 mg daily reduces migraine frequency by roughly 40 to 50 percent in responders [9].

Side effects include fatigue, exercise intolerance, cold extremities, depression, and sexual dysfunction. Beta-blockers are a particularly good choice for migraine patients who also have hypertension, performance anxiety, or essential tremor. They should be avoided in patients with asthma, severe bradycardia, or decompensated heart failure.

Anticonvulsants

Two anticonvulsants have strong evidence for migraine prevention:

Topiramate (Topamax) is FDA-approved for migraine prevention at doses of 50 to 100 mg daily. It reduces migraine frequency effectively but carries a notable side effect burden, including cognitive difficulties (often called “brain fog” or “dopamax” by patients), paresthesias, weight loss, kidney stones, and metabolic acidosis [10]. It is teratogenic and absolutely contraindicated in pregnancy.

Valproate/divalproex sodium (Depakote) is also FDA-approved and effective at doses of 500 to 1500 mg daily. Side effects include weight gain, tremor, hair loss, and liver toxicity. Like topiramate, it is teratogenic and requires reliable contraception in women of reproductive age [10].

Antidepressants

Among antidepressants, amitriptyline (a tricyclic) has the most evidence for migraine prevention, typically used at doses of 10 to 75 mg at bedtime, well below the doses used for depression [11]. It is particularly useful for patients with comorbid insomnia or tension-type headache. Common side effects include dry mouth, weight gain, constipation, and morning drowsiness.

Venlafaxine (an SNRI) at doses of 150 mg daily is another option with moderate evidence, and it may be better tolerated than tricyclics in some patients [11]. SSRIs (like fluoxetine and sertraline) have weak evidence for migraine prevention and are generally not recommended as primary preventive therapy.

OnabotulinumtoxinA (Botox)

Botox injections are FDA-approved specifically for chronic migraine (15 or more headache days per month). The PREEMPT protocol involves 31 to 39 injections across 7 specific head and neck muscle sites every 12 weeks [12]. Response may take two to three treatment cycles to become apparent.

Botox works through inhibition of peripheral nociceptive signaling and has been shown to reduce headache days by 8 to 9 per month in chronic migraine patients [12]. It is generally well tolerated, with neck pain and injection site discomfort being the most common complaints. It is not typically effective for episodic migraine (fewer than 15 headache days per month).

How to Choose the Right Migraine Medication

Selecting a migraine medication is a collaborative process between you and your physician. Several factors guide the decision [2]:

• Attack frequency: Fewer than 4 migraine days per month may be managed with acute treatment alone. More frequent attacks warrant adding prevention.
• Comorbid conditions: Hypertension favors beta-blockers. Depression may favor antidepressants. Epilepsy may favor anticonvulsants. Cardiovascular disease rules out triptans.
• Side effect profile: Weight concerns may steer away from valproate or amitriptyline. Cognitive concerns argue against topiramate.
• Speed of onset needed: CGRP antibodies and Botox work slowly. Patients needing rapid results may prefer medications with faster onset of preventive benefit.
• Route of administration: Some patients prefer daily pills. Others prefer monthly injections they do not have to remember each day.
• Cost and insurance coverage: Older generic medications (beta-blockers, tricyclics, topiramate) are far less expensive than CGRP antibodies or gepants.

Medication Overuse Headache: A Critical Warning

One of the most important concepts in migraine management is medication overuse headache (MOH), previously called rebound headache. Using acute migraine medications too frequently, typically more than 10 days per month for triptans or opioids, or more than 15 days per month for simple analgesics, can paradoxically worsen headache frequency and severity [13].

MOH affects an estimated 1 to 2 percent of the general population and up to 50 percent of patients in headache specialty clinics [13]. The treatment involves carefully withdrawing the overused medication (often with a bridge therapy like a short steroid taper or nerve block) and starting appropriate preventive therapy. Gepants and CGRP antibodies appear to carry a lower risk of MOH compared to older acute treatments, though long-term data are still accumulating [4].

Newer and Emerging Treatments

The migraine treatment landscape continues to evolve. Atogepant (Qulipta), an oral gepant taken daily for prevention, has shown efficacy in both episodic and chronic migraine and offers a convenient oral preventive option for patients who prefer pills over injections [14]. Dual-mechanism devices combining neuromodulation with pharmacotherapy are in development. Research into glutamate receptor modulators, pituitary adenylate cyclase-activating polypeptide (PACAP) inhibitors, and other novel targets may yield additional treatment options in the coming years [15].

Related Reading

• Migraine: Complete Guide
• Migraine Treatment Options
• Migraine Relief Strategies
• Understanding Migraine Aura

References

1. Silberstein SD. “Preventive migraine treatment.” Continuum (Minneapolis, Minn.). 2015;21(4):973-989. doi:10.1212/CON.0000000000000199
2. American Headache Society. “The American Headache Society position statement on integrating new migraine treatments into clinical practice.” Headache. 2019;59(1):1-18. doi:10.1111/head.13456
3. Tfelt-Hansen P, De Vries P, Saxena PR. “Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.” Drugs. 2000;60(6):1259-1287. doi:10.2165/00003495-200060060-00003
4. Lipton RB, Dodick DW, Ailani J, et al. “Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial.” JAMA. 2019;322(19):1887-1898. doi:10.1001/jama.2019.16711
5. Rabbie R, Derry S, Moore RA. “Ibuprofen with or without an antiemetic for acute migraine headaches in adults.” Cochrane Database of Systematic Reviews. 2013;(4):CD008039. doi:10.1002/14651858.CD008039.pub3
6. Goadsby PJ, Wietecha LA, Dennehy EB, et al. “Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.” Brain. 2019;142(7):1894-1904. doi:10.1093/brain/awz134
7. Colman I, Brown MD, Innes GD, et al. “Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials.” BMJ. 2004;329(7479):1369-1373. doi:10.1136/bmj.38281.595718.7C
8. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. “CGRP as the target of new migraine therapies: successful translation from bench to clinic.” Nature Reviews Neurology. 2018;14(6):338-350. doi:10.1038/s41582-018-0003-1
9. Linde K, Rossnagel K. “Propranolol for migraine prophylaxis.” Cochrane Database of Systematic Reviews. 2004;(2):CD003225. doi:10.1002/14651858.CD003225.pub2
10. Silberstein SD, Holland S, Freitag F, et al. “Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults.” Neurology. 2012;78(17):1337-1345. doi:10.1212/WNL.0b013e3182535d20
11. Xu XM, Liu Y, Dong MX, et al. “Tricyclic antidepressants for preventing migraine in adults.” Medicine. 2017;96(22):e6989. doi:10.1097/MD.0000000000006989
12. Dodick DW, Turkel CC, DeGryse RE, et al. “OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.” Headache. 2010;50(6):921-936. doi:10.1111/j.1526-4610.2010.01678.x
13. Diener HC, Holle D, Solbach K, Gaul C. “Medication-overuse headache: risk factors, pathophysiology and management.” Nature Reviews Neurology. 2016;12(10):575-583. doi:10.1038/nrneurol.2016.124
14. Ailani J, Lipton RB, Goadsby PJ, et al. “Atogepant for the preventive treatment of migraine.” New England Journal of Medicine. 2021;385(8):695-706. doi:10.1056/NEJMoa2035908
15. Ashina M, Hansen JM, Do TP, et al. “Migraine and the trigeminovascular system: 40 years and counting.” Lancet Neurology. 2019;18(8):795-804. doi:10.1016/S1474-4422(19)30185-1